Welcome to our dedicated page for Absci SEC filings (Ticker: ABSI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Reading Absci鈥檚 dense biotech disclosures can feel like parsing a lab notebook written in code. R&D capitalization rules, milestone accounting, and rapidly evolving regulatory language turn every 10-K into a puzzle. That鈥檚 why our SEC filings hub tackles the complexity head-on, turning 鈥淎bsci insider trading Form 4 transactions鈥� and clinical-stage risk factors into clear, decision-ready insights.
Need the latest numbers? Each Absci quarterly earnings report 10-Q filing is indexed the moment it posts to EDGAR, with AI-powered summaries highlighting cash runway, collaboration revenue swings, and pipeline spend. Material news breaks fast too鈥攐ur platform pushes alerts and plain-English takeaways for every Absci 8-K material events explained entry, so you know exactly what changed and why.
Curious whether executives are buying ahead of data readouts? Track Absci Form 4 insider transactions real-time and dive deeper with Absci executive stock transactions Form 4 tables already totaled for you. Preparing a valuation model? The Absci annual report 10-K simplified section distills 200-plus pages into key financials, IP assets, and regulatory risks. Governance analysts can compare board pay with the Absci proxy statement executive compensation snapshot, while newcomers benefit from understanding Absci SEC documents with AI through concise, jargon-free briefs.
- AI summaries translate complex biotech language into investor-ready points.
- AG真人官方-time feeds cover every form鈥攆rom 10-K to 8-K鈥攆or complete Absci earnings report filing analysis.
- Searchable database links each disclosure to the questions professionals actually ask.
Spend less time decoding filings and more time acting on insights鈥攐ur platform turns Absci鈥檚 regulatory maze into a straight path.
Absci Corporation (NASDAQ: ABSI) is issuing 16.67 million new common shares at $3.00 each via a Rule 424(b)(5) prospectus supplement, generating gross proceeds of $50.0 million. After deducting $3.0 million in underwriting fees (6%) and roughly $0.35 million in expenses, estimated net proceeds total $46.7 million. Underwriters鈥擬organ Stanley, J.P. Morgan, Jefferies and TD Cowen鈥攈old a 30-day option for an additional 2.50 million shares that could lift net proceeds to about $53.7 million.
The offering will expand outstanding shares from 127.5 million (31 Mar 25) to 144.2 million (or 146.7 million if the option is exercised), an immediate increase of roughly 13% in share count. As-adjusted tangible book value per share rises from $1.21 to $1.40, leaving new investors with $1.60 per-share dilution versus the $3.00 purchase price. The deal is priced at an 8% discount to the 23 Jul 25 closing price of $3.52.
Management intends to deploy the cash to advance internal antibody programs (ABS-101, ABS-201), enhance its AI-driven Integrated Drug Creation鈩� platform, and for general corporate purposes, with flexibility to pursue complementary acquisitions. Preliminary, unaudited liquidity was $117.5 million in cash and investments as of 30 Jun 25; the raise meaningfully extends runway toward key clinical milestones expected in 2026. Absci remains a 鈥渟maller reporting company鈥� and flags typical biotechnology and capital-markets risks, including potential share-price pressure from the enlarged float.
Meritage Homes (MTH) Q2-25 10-Q highlights
- Revenue: $1.624 bn, -4% YoY; home-closing revenue $1.616 bn (-5%).
- Gross profit: $341 m vs $440 m; home-closing gross margin down to 21.1% from 25.9%.
- Net earnings: $146.9 m, -37%; Diluted EPS: $2.04 vs $3.15.
- Six-month results: Revenue $2.982 bn (-6%); Net earnings $269.7 m (-35%).
- Cash & equivalents: $930 m (鈫�43% YTD) after $500 m 5.65% senior notes due 2035; Total debt: $1.802 bn vs $1.307 bn; no revolver borrowings.
- Operating cash flow: -$28.9 m; inventory investment 鈫�$224.6 m.
- Equity: $5.269 bn; buybacks $90 m (674k shares) & dividends $61 m in 1H-25.
- Backlog/communities: 312 active communities; base prices $170k-$1.04 m.
- Tax rate: 23.9% vs 22.1%, reflecting tougher 搂45L energy-credit standards.
- Covenants: leverage ratio <60% and min tangible net worth $3.3 bn; in compliance.
Overall, softer demand and mix pressure reduced margins and earnings, while balance-sheet liquidity remains strong but leverage has increased due to new long-term debt.
Form 4 filing: Booz Allen Hamilton (BAH) director Michele A. Flournoy reported a Code G (gift) transaction dated 22-Jul-2025. She transferred 13,647 Class A shares to the Michele Angelique Flournoy Living Trust for $0 consideration as part of estate-planning.
Following the transfer, Flournoy now holds 3,912 shares directly and 13,647 shares indirectly through the trust, keeping her total beneficial ownership unchanged at 17,559 shares. No open-market sale or purchase occurred and no cash changed hands; this filing solely reclassifies ownership from direct to indirect.
The event carries minimal market impact: share count in public float is unaffected, and insider stake remains the same. Investors typically view such transfers as neutral housekeeping rather than a signal on the company鈥檚 outlook.
On July 9, 2025, Kite AG真人官方ty Group Trust (NYSE: KRG) submitted a Form 4 reporting that director Victor J. Coleman acquired 524 common share units on July 1, 2025. The units were recorded at a price of $0, indicating a routine equity grant awarded as part of director compensation. After the transaction, Coleman鈥檚 direct ownership stands at 96,425 KRG shares. No derivative securities were involved, and there is no indication of open-market buying or selling. The filing reflects a modest, non-cash increase in insider holdings and is not likely to materially affect Kite AG真人官方ty Group鈥檚 share structure or market outlook.
Absci Corporation (NASDAQ: ABSI) filed an 8-K announcing the appointment of Mary Szela, current CEO, President and Director of Trisalus Life Sciences, to Absci鈥檚 Board of Directors effective July 7, 2025. Her addition expands the Board from six to seven members and creates a third Class III seat, with a term expiring at the 2027 annual meeting.
Under the company鈥檚 Non-Employee Director Compensation Policy, Ms. Szela will receive an initial stock option for 178,400 shares of common stock, priced at the NASDAQ closing price on the grant date. The option vests in equal monthly installments over three years and accelerates to full vesting upon a defined 鈥淪ale Event.鈥� She will also earn a standard $40,000 annual cash retainer.
The filing confirms there are no related-party transactions, family relationships, or special arrangements tied to her selection, and Ms. Szela will sign Absci鈥檚 standard indemnification agreement. Other than this governance change, the 8-K contains no financial results or strategic transaction disclosures.
FAQ
What is the current stock price of Absci (ABSI)?
What is the market cap of Absci (ABSI)?
What is the core business of Absci Corp?
How does Absci integrate AI into its drug discovery process?
What differentiates Absci from traditional drug discovery companies?
Who are some of Absci's key collaborators?
In which therapeutic areas is Absci active?
How does the Integrated Drug Creation鈩� platform benefit drug development?
What challenges does Absci face in the competitive biopharma landscape?
